Lisata Therapeutics Book Value Per Share vs. Cash And Equivalents
| LSTA Stock | USD 2.88 0.04 1.41% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 5.93261489 | Current Value 6.23 | Quarterly Volatility 3.2 K |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.6 |
|
|
For Lisata Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lisata Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lisata Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lisata Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lisata Therapeutics over time as well as its relative position and ranking within its peers.
Lisata |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.51) | Return On Assets (0.29) | Return On Equity (0.44) |
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lisata Therapeutics Cash And Equivalents vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lisata Therapeutics's current stock value. Our valuation model uses many indicators to compare Lisata Therapeutics value to that of its competitors to determine the firm's financial worth. Lisata Therapeutics is currently regarded as number one stock in book value per share category among its peers. It is rated below average in cash and equivalents category among its peers creating about 12,354,435 of Cash And Equivalents per Book Value Per Share. At present, Lisata Therapeutics' Book Value Per Share is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lisata Therapeutics' earnings, one of the primary drivers of an investment's value.Lisata Cash And Equivalents vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Lisata Therapeutics |
| = | 5.91 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Lisata Therapeutics |
| = | 72.99 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Lisata Cash And Equivalents Comparison
Lisata Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Lisata Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lisata Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lisata Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Lisata Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Lisata Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -42 K | -44.1 K | |
| Operating Income | -25.7 M | -27 M | |
| Income Before Tax | -23.2 M | -24.3 M | |
| Total Other Income Expense Net | 2.5 M | 2.7 M | |
| Net Loss | -20.8 M | -21.9 M | |
| Income Tax Expense | -2.3 M | -2.2 M | |
| Net Loss | -20.8 M | -21.9 M | |
| Net Loss | -24.7 M | -26 M | |
| Change To Netincome | 5.2 M | 5.5 M | |
| Net Loss | (2.58) | (2.71) | |
| Income Quality | 0.96 | 1.01 | |
| Net Income Per E B T | 0.90 | 0.48 |
Lisata Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lisata Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lisata Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lisata Therapeutics' important profitability drivers and their relationship over time.
Use Lisata Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lisata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lisata Therapeutics will appreciate offsetting losses from the drop in the long position's value.Lisata Therapeutics Pair Trading
Lisata Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Lisata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lisata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lisata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lisata Therapeutics to buy it.
The correlation of Lisata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lisata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lisata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lisata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lisata Therapeutics position
In addition to having Lisata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ESG Investing Thematic Idea Now
ESG Investing
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
To fully project Lisata Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lisata Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lisata Therapeutics' income statement, its balance sheet, and the statement of cash flows.